Previous 10 | Next 10 |
2024-01-21 02:50:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. In the quarter ended December 31, 2023, Baron Health Care Fund® (the Fund) advanc...
2024-01-19 20:06:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-09 09:00:00 ET Summary Chris DeMuth Jr. discusses his position in uranium and his belief that nuclear energy will play a significant role in the future of energy production. He also updates us on SHF Holdings, a fintech company serving the cannabis industry, and predicts i...
2024-01-08 08:31:52 ET Summary The healthcare sector was flat in 2023 year as a result of some unique issues. Drug price regulation will be a serious challenge for the sector this year. Defensive healthcare industry groups should do well during the first half and biotechnology...
NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., chief executive officer, will provide a corporate overview at...
2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...
2023-12-29 11:23:28 ET Summary Shares of Viridian Therapeutics underperformed this year. Negative biotech sentiment was partly to blame, as well as Tepezza's Y/Y net sales declines, and some internal turmoil with two CEO changes. These events overshadowed many positive develop...
2023-12-21 11:42:39 ET More on Immunovant, Roivant Sciences, etc. 2024 - Liquidia, Burford, And Roivant Immunovant: Q3 Earnings, Navigating Risks And Rewards In The Autoimmune Arena Roivant Sciences Ltd. (ROIV) Q2 2023 Earnings Call Transcript Immunovant gain...
2023-12-21 07:15:02 ET Deutsche Bank analyst issues BUY recommendation for IMVT on December 21, 2023 07:36AM ET. The previous analyst recommendation was Buy. IMVT was trading at $36.18 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curre...
NEW YORK, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT) , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that results from the initial cohort of patients in an ongoing 24-week Phase 2 clinical tri...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Following a recently completed Type B meeting with the FDA, Immunovant is on track to initiate 4 to 5 potentially registrational studies for its lead asset IMVT-1402 in endocrinology, neurology, and other therapeutic areas over this fiscal year ending March 31, 2025 Topline data from the bato...